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The immune tolerogenic effects of IDO1 (indoleamine 2,3-dioxygenase 1) have been well documented and ge-
netic studies in mice have clearly established the signiﬁcance of IDO1 in tumor promotion. Dichotomously, the
primary inducer of IDO1, the inﬂammatory cytokine IFNγ (interferon-γ), is a key mediator of immune-based
tumor suppression. One means by which IFNγ can exert an anti-cancer effect is by decreasing tumor neovascu-
larization. We speculated that IDO1 might contribute to cancer promotion by countering this anti-neovascular
effect of IFNγ, possibly through IDO1-potentiated elevation of the pro-tumorigenic inﬂammatory cytokine IL6
(interleukin-6). In this study, we investigated how genetic loss of IDO1 affects neovascularization in mouse
models of oxygen-induced retinopathy and lungmetastasis. Neovascularization in bothmodels was signiﬁcantly
reduced inmice lacking IDO1, was similarly reduced with loss of IL6, and was restored in both cases by concom-
itant loss of IFNγ. Likewise, the lack of IDO1 or IL6 resulted in reduced metastatic tumor burden and increased
survival, which the concomitant loss of IFNγ abrogated. This insight into IDO1's involvement in pro-tumorigenic
inﬂammatory neovascularization may have important ramiﬁcations for IDO1 inhibitor development, not only in
cancer where clinical trials are currently ongoing, but in other disease indications associated with neovasculari-
zation as well.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Chronic inﬂammation provides a microenvironmental context
which can foster tumor promotion through a complex and dynamic
interplay between stroma and tumor that remains an area of active
investigation (Peek et al., 2005). In an experimental model of two
stage chemical carcinogenesis, wherein mutagenic tumor initiation
and inﬂammatory tumor promotion are distinctly separable, IDO1
(indoleamine 2,3-dioxygenase 1) has been identiﬁed as a vital compo-
nent of the inﬂammatory tumor promoting milieu (Muller et al.,
2008). Enzymatically, IDO1 catabolizes the essential amino acid trypto-
phan, but it is not the enzyme responsible for maintaining normal tryp-
tophan homeostasis, which instead is the role of the evolutionarily
convergent liver enzyme TDO2 (tryptophan dioxygenase 2). Rather,
IDO1 can be expressed in a variety of tissues, particularly alongmucosal
surfaces, and is strongly induced by the inﬂammatory cytokine IFNγ
(interferon-γ) (Taylor and Feng, 1991). The conceptualization of IDO1
as a regulator of immune function emerged fromobservations that tryp-
tophan depletion by IDO1 could suppress cytotoxic T cell activation
(Munn et al., 1999). The demonstration that an IDO1 pathway inhibitor
1MT (1-methyl-tryptophan) could elicit T cell-dependent rejection of
allogeneic mouse concepti (Munn et al., 1998) dramatically cemented
the concept of IDO1 as a tolerogenic actor. Subsequent ﬁndings linking
loss of the tumor suppressor gene Bin1 to IDO1 dysregulation and tu-
moral immune escape (Muller et al., 2005) provided experimental sub-
stantiation for the corollary proposition that tumors might appropriate
this mechanism for protecting the ‘foreign’ fetus to overcome tumor
immunosurveillance. Additionally, while IDO1 can contribute to tumor
development when expressed directly within tumor cells, (where
immunoediting may be at play), its expression within non-malignant
stroma has been shown to be contributory to tumor development as
well (Munn et al., 2004).
A relatively high basal level of IDO1 is expressed in the lungs, andwe
previously determined that IDO1 loss was associated with markedly
reduced pulmonary tumor burden and increased survival both in a
transgenic mouse model of autochthonous, mutant KRAS-driven lung
carcinoma and in an orthotopic graft model of metastatic breast cancer
(Smith et al., 2012). Unexpectedly, a signiﬁcant reduction in normal
lung vascularization was also associated with the loss of IDO1,
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suggesting a possible role for IDO1 in supporting blood vessel formation
(Smith et al., 2012). Neovascularization is critical for tumor outgrowth
(Cao et al., 2011). However, unlike the tightly regulated process of nor-
mal tissue vascularization, tumor neovascularization is characterized by
excessive and disorganized growth of blood vessels much like that in-
duced by ischemia in tissues such as the retina and lungs (Carmeliet,
2003). One important check on tumor neovascularization is the inﬂam-
matory cytokine IFNγ. Indeed, the loss of tumor vasculature elicited by
IFNγ, rather than direct tumor cell killing, has been implicated as
being the primarymechanism for both CD4+ and CD8+ T cell-mediated
tumor rejection (Qin and Blankenstein, 2000, Qin et al., 2003). However,
IFNγ also drives IDO1, leading us to predict that IDO1 may act in a
negative feedback capacity to dampen the tumor suppressive, anti-
neovascular effects of IFNγ. A possible mechanistic explanation is
suggested by our recent determination that IDO1 can potentiate the in-
duction of another inﬂammatory cytokine IL6 (interleukin 6) (Smith et
al., 2012), which has been implicated as a pro-neovascular factor for tu-
mors (Middleton et al., 2014). In this report, we present evidence that
IDO1 does indeed have a critical role in supporting neovascularization
that corresponds with its integration at the interface between these
two competing inﬂammatory cytokines, IFNγ and IL6.
2. Materials and Methods
2.1. Transgenic Mouse Strains
Congenic Ido1−/− mice on both BALB/c and C57BL/6 strain back-
grounds were provided by A. Mellor (GHSU). The development of
congenic Ido2−/− mice on the BALB/c strain background has been de-
scribed previously (Metz et al., 2014). Congenic Ifng−/− and Il6−/−
mouse strains on the BALB/c strain background and WT BALB/c and
C57BL/6 strains were acquired from the Jackson Laboratory. All studies
involvingmicewere approved by the Lankenau Institute forMedical Re-
search IACUC and conform with AAALAC guidelines.
2.2. 4T1 Tumor Cell Metastasis
Pulmonarymetastasis studieswith the4T1mousemammary carcino-
ma-derived cell line (Aslakson and Miller, 1992) were carried out by
injecting 1 × 104 cells in 50 μl serum free medium into the number 4
mammary fatpad to establish an orthotopic tumorwhich then spontane-
ously metastasized to the lungs. For visualization of the pulmonary
metastasis burden, lungs were inﬂated with 15% India ink dye, washed,
and bleached in Fekete's solution. For immunoﬂuorescence detection of
pulmonary metastasis vasculature, lungs were inﬂated with 50% OCT
and frozen in OCT blocks followed by 4 μm sectioning using the CryoJane
tape transfer system. Blood vessels within the metastatic nodules were
visualized by ﬂuorescence staining with rabbit anti-Caveolin1 polyclonal
antibody (Cell Signaling, Cat. #3238S). For quantitatively evaluating ves-
sel density within the metastatic nodules, multiple ﬁelds were acquired
per mouse lung on a Zeiss inverted microscope with 40× objective. The
pixel density corresponding to the positive Cav1 signal per ﬁeld was
determined in Adobe Photoshop, and these values were then averaged
to determine the overall mean value per mouse. For IDO1 inhibitor
treatment studies, mice bearing established metastases at 3.5 weeks
following 4T1 engraftment were administered 50 mg/kg epacadostat
(ChemieTek) in 100 μl vehicle (3% N,N-dimethylacetamide, 10% 2-
hydroxylpropyl-β-cyclodextrin) by oral gavage b.i.d. over 72 h at which
point the animals were euthanized for analysis. Positive control animals
were administered a single i.p. injection of 50 mg/kg cyclophosphamide
(Baxter) in 100 μl sterile saline and euthanized 72 h later for analysis.
2.3. Oxygen-induced Retinopathy
Neovascularization studies in the OIR model were carried out as de-
scribed (Connor et al., 2009). Neonatalmicewere housed in anOxyCycler
chamber set to 75% oxygen from day 7 to day 12 postpartum (P7-P12).
At P12, the neonates were removed from the chamber and subsequent-
ly maintained under normoxic conditions until P17. To evaluate the
retinal vasculature, the eyes were ﬁxed in 4% paraformaldehyde and
methanol. Retinas were then isolated under a dissecting microscope,
stained with Isolectin B4-Alexa488, and ﬂatmounted for ﬂuorescence
microscopy. Overlapping images were obtained on a Zeiss inverted mi-
croscope with 2.5× objective. Composite images were assembled and
quantitative analysis of neovascularization was performed using
Adobe Photoshop as described (Connor et al., 2009). For IDO1 inhibitor
treatment studies, neonates were administered 50 mg/kg epacadostat
in 50 μl (3% N,N-dimethylacetamide, 10% 2-hydroxylpropyl-β-cyclo-
dextrin) by oral gavage b.i.d. from P12-P17 at which point the animals
were euthanized for analysis. Positive control animals were adminis-
tered i.p. injections of 50 mg/kg ethyl pyruvate (Aldrich) in modiﬁed
Ringer's solution (130 mM sodium, 4 mM potassium, 2.7 mM calcium,
139 mM chloride) in a total volume of 50 μl b.i.d. from P12–P17.
2.4. Intravitreal Injections
For siRNA treatments (siIdo1, siVegfa Acell smart pools; GE
Healthcare, Dharmacon), a single injection of 1 μg siRNA in 1 μl PBS
was administered at P14, with the targeted siRNA injected into one
eye and the non-targeted control siRNA injected into the contralateral
eye. Prior to injection, the topical anesthetic Alcaine (0.5% proparacaine
hydrochloride ophthalmic solution) was applied to the eyelids. Eyes
were injected under a dissecting microscope through the cornea into
the vitreous humor using a 33 gauge needle attached to a 2.5 μl glass sy-
ringe. All studies were concluded at P17 for evaluation of the impact on
retinal neovascularization as described above.
2.5. Statistical Analysis
Graphing and statistical analysis was performed using Prism 6
(GraphPad Software, Inc.). Bar graphs were plotted as means ± SEM
with statistical signiﬁcance determined, as appropriate, by unpaired,
2-tailed Student's t-test (except for siRNA studies that were evaluated
by paired t-test) or by one-way ANOVA with Tukey's multiple compar-
ison test or Dunnett's multiple comparison test. Signiﬁcance for
Kaplan-Meier survival curves was determined by 2-group log-rank test.
P value ranges are indicated as follows: ****, P b 0.0001; ***, P b 0.001;
**, P b 0.01; *, P b 0.05; ns, not signiﬁcant.
3. Results
3.1. IDO1 Loss Results in Reduced Neovascularization
Ido1−/− (Ido1 nullizygous) mice challenged with orthotopically
engrafted 4T1 mammary adenocarcinoma tumors exhibited a marked
delay in pulmonary metastasis development relative to their WT (wild
type) counterparts (Fig. S1a), consistent with previously published re-
sults (Smith et al., 2012). When metastases did form in Ido1−/− hosts,
they were observed to have a lower vascular density than those formed
in WT animals (Fig. 1a), the signiﬁcance of which was conﬁrmed by
quantitative analysis (Fig. 1b; Δ = 2.6-fold, P b 0.01). This ﬁnding
suggests that neovascularization of the pulmonary 4T1 metastases is
impaired in mice lacking IDO1, however, direct comparative analysis
is complicated by the pronounced differential in metastatic tumor out-
growth between Ido1−/− and WT animals.
To assess the impact of IDO1 loss on neovascularization independent
of other possible effects on tumor growth, studies were performed in a
mouse model of OIR (oxygen-induced retinopathy). Initially developed
for studying retinopathy of prematurity, OIR has been demonstrated to
be a reliable and quantiﬁable system for modeling pathological angio-
genesis (Connor et al., 2009), and this experimental model has since
been employed more broadly as a surrogate system in studies of
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Fig. 1. IDO1 loss is associated with reduced neovascularization in pulmonary metastasis and oxygen-induced retinopathy models. (a) Representative images of immunoﬂuorescent
staining of blood vessels with anti-Cav1 (red) and of nuclei with DAPI (blue) within 4T1 lung metastases in WT and Ido1−/−mice. (b) Quantitative assessment of neovascular density
as marked by anti-Cav1 positive staining within 4T1 lung metastases in WT and Ido1−/− mice (N ≥ 3 mice). Graphed as means ± SEM with signiﬁcance determined by 2-tailed
Student's t-test (c) Representative images of B4-Alexa488-isolectin staining of blood vessels in retinal ﬂatmounts at P17 from WT and Ido1−/− neonates maintained either under
constant normoxia or exposed to hyperoxia from P7-P12 to induce OIR. At far right are higher magniﬁcations to highlight the difference in neovascular tufts between WT and Ido1−/−
mice. (d) Quantitative assessment at P17 of neovascular area over total retinal area for WT, Ido1−/−, and Ido2−/− OIR cohorts (N ≥ 17 eyes). Cohorts maintained under constant
normoxia are also included for baseline comparison (N ≥ 10 eyes). Graphed as means ± SEM with signiﬁcance determined by one-way ANOVA with Tukey's multiple comparison test.
(e) Quantitative comparison at P17 of neovascular area over total retinal area between WT OIR-elicited cohorts that received a single intraocular injection at P14 of the indicated
siRNAs targeting Ido1, Vegfa, or the corresponding Ntc (Non-target control) (N ≥ 8 eyes). Graphed as means ± SEM with signiﬁcance determined by paired, 2-tailed Student's t-test. (f)
Quantitative comparison at P17 of avascular area over total retinal area for WT and Ido1−/− OIR cohorts (N ≥ 27 eyes). Graphed as means ± SEM with signiﬁcance determined by 2-
tailed Student's t-test.
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tumor neovascularization (Palmer et al., 2012, Stahl et al., 2012). To test
the hypothesis that IDO1 supports neovascularization,we examined the
impact of Ido1 gene disruption in theOIRmodel. Representativemicros-
copy images of B4-Alexa488-isolectin stained retinal ﬂat mounts from
WT and Ido1−/− mice are shown, including higher magniﬁcation im-
ages speciﬁcally focused on the characteristic neovascular tufts (Fig.
1c). From these images it is apparent that the extent of neovasculariza-
tion is markedly reduced in the Ido1−/− mouse retina. Quantitative
comparison between the WT and Ido1−/− groups, (Fig. 1d), conﬁrmed
that a signiﬁcant decrease in OIR-associated neovascularization was as-
sociated with the lack of IDO1 expression (Δ= 3.1-fold, P b 0.001). A
similar outcome was observed in a different inbred mouse strain back-
ground (Fig. S1b). This ﬁnding clearly establishes an important role for
IDO1 in this tumor-independent model of neovascularization.
To assess the speciﬁcity of the requirement for IDO1 in OIR-associat-
ed neovascularization,mice lacking the related paralog IDO2were eval-
uated. In contrast to mice lacking IDO1, Ido2−/− mice exhibited no
signiﬁcant impact onOIR-associated neovascularization (Fig. 1d). To de-
terminewhether the diminished retinal neovascularization observed in
Ido1−/− mice is attributable to a direct effect of IDO1 loss within the
context of the eye rather than a systemic developmental deﬁciency,
siRNA targeting the Ido1messagewas delivered by intravitreal injection
into one eye pairedwith non-target control siRNA injected into the con-
tralateral eye. Acute, local targeting Ido1 expression in this manner pro-
duced a signiﬁcant decrease in neovascularization (Δ = 2.4-fold,
P b 0.0001) that was comparable to the effect observed with a positive
control siRNA directed against Vegfa (Fig. 1e).
Additional control experiments were carried out to assess the
broader impact of IDO1 loss on normal retinal vascularization. The re-
growth of normal retinal vessels that also occurs in OIR can be quantita-
tively evaluated in whole mount retinas by assessment of the avascular
area (Connor et al., 2009). The avascular region was signiﬁcantly
reduced in Ido1−/− animals relative to their wild type counterparts
(Δ=2.8-fold, P b 0.0001) (Fig. 1f), indicative of an actual improvement
in normal vessel regrowth in mice lacking IDO1. In normoxic controls,
quantitative assessment of normal vascular density at P17 failed to
demonstrate any effect of IDO1 loss (Fig. S1c). Likewise, at P12, when
the oxygen concentration is shifted from hyperoxia to normoxia to in-
duce neovascularization, there was no apparent difference between
the retinas of WT and Ido1−/−mice maintained either under constant
normoxia or exposed to hyperoxia (Fig. S2). Taken together, these re-
sults are consistent with the loss of IDO1 negatively affecting only the
pathologic blood vessel formation responsible for neovascularization.
The genetic data suggest that pharmacologic inhibitors of IDO1 en-
zymatic activity may have therapeutic potential for reducing patholog-
ical neovascularization. To directly test this possibility, a small molecule
inhibitor of IDO1, epacadostat, was administered by oral gavage to neo-
nates following OIR elicitation. Relative to vehicle alone, epacadostat
treatment resulted in a signiﬁcant reduction in retinal neovasculariza-
tion (Δ= 1.8-fold, P b 0.001), which was comparable to that achieved
with a positive control compound, ethyl pyruvate (Lee et al., 2013)
(Fig. 2a,b). Likewise, when epacadostat was administered by oral ga-
vage over a 72 h period tomicewith established 4T1 pulmonarymetas-
tases, epacadostat treatment resulted in a signiﬁcant reduction in
metastatic tumor neovascularization relative to vehicle alone (Δ =
3.2-fold, P b 0.01) that was comparable to the effect of the positive con-
trol compound cyclophosphamide (Ibe et al., 2001) (Fig. 2c,d). These re-
sults conﬁrm that blocking the enzymatic activity of IDO1 through
pharmacologic inhibition is sufﬁcient to interfere with the ability of
IDO1 to support neovascularization.
3.2. IFNγ is Required for Reduced Neovascularization and Increased Metas-
tasis Resistance Resulting from IDO1 Loss
The inﬂammatory cytokine IFNγ is a major inducer of IDO1. There is
substantial evidence that IFNγ is critical for effective anti-tumor
immunity (Beatty and Paterson, 2001), and IFNγ-elicited reduction of
the tumor neovasculature has been proposed as a mechanism of action
(Qin and Blankenstein, 2000, Qin et al., 2003). To test the hypothesis
that IDO1 acts as a negative feedback check on the anti-neovascular ef-
fect of IFNγ, we bred double knockoutmice nullizygous for both the Ifng
and Ido1 alleles to evaluate in the OIR model. The concomitant loss of
IFNγ togetherwith IDO1mitigated the reduction in OIR-associated neo-
vascularization observed with the loss of IDO1 alone (Fig. 3a,b), such
that no signiﬁcant difference could be detected between the Ifng−/−
Ido1−/− mice and the WT controls (Fig. 3b). The importance of IFNγ
to the reduction in OIR-associated neovascularization observed with
IDO1 loss was further tested by intravitreal injection of anti-IFNγ neu-
tralizing antibody. Ido1−/− mice demonstrated a signiﬁcant recovery
of neovascularization in anti-IFNγ antibody treated eyes compared to
the contralateral eyes treated with isotype matched negative control
antibody (Fig. S3). Thus both experimental approaches yielded data
consistent with the hypothesis that IDO1 supports neovascularization
primarily by counteracting the negative impact of IFNγ on this process.
To examine the relevance of these ﬁndings from the OIR model in
the context of a tumor setting, we examined the impact that loss of
both IFNγ and IDO1 in the host animal have on neovascularization in
4T1pulmonarymetastases.Metastases that formed in Ido1−/− hosts ex-
hibited a signiﬁcantly lower vascular density relative to those that
formed in the wild type controls, while the concomitant loss of both
IFNγ and IDO1 in double knockout mice completely negated the effect
on 4T1 metastasis neovascularization of IDO1 loss alone (Fig. 3c,d).
We have previously reported that loss of IDO1 provides a signiﬁcant
survival beneﬁt to mice challenged orthotopically with 4T1 tumors
due to reduced pulmonary metastasis burden (Smith et al., 2012). In
this context, the concomitant loss of IFNγ together with IDO1 in double
knockout mice negated both the reduction in pulmonary metastasis
burden and the survival beneﬁt observed with the loss of IDO1 alone
(Fig. 3e,f). These data demonstrate a striking correspondence between
the countervailing effects of IDO1 and IFNγ on neovascularization and
metastasis survival, suggesting that the antagonistic effect that IDO1
has on the anti-neovascular activity of IFNγ may be directly linked to
its pro-tumorigenic role in this metastasis model.
3.3. IL6 Loss Results in IFNγ-dependent Reduction in Neovascularization
and Increase in Metastasis Resistance
Previously we reported that loss of IDO1 was associated with atten-
uated IL6 induction in the 4T1 metastasis model and that metastasis
susceptibility could be restored by provision of exogenous IL6 (Smith
et al., 2012). To examine whether IL6 has a corresponding involvement
in neovascularization, we examined the impact that genetic loss of IL6
has in OIR. Similar to the loss of IDO1, Il6−/− animals exhibited a clear
reduction in neovascularization, which was reversed by the concomi-
tant loss of IFNγ to a level thatwas indistinguishable from that observed
with IFNγ loss alone (Fig. 4a,b). IL6 loss similarly affected neovasculari-
zation in 4T1 lungmetastases,with themetastatic tumors obtained from
Il6−/− animals exhibiting a signiﬁcantly reduced vascular density rela-
tive to the wild type controls (Fig. 4c,d). Again, the concomitant loss of
IFNγ abrogated the reduction in vascular density observed with the
loss of IL6 alone (Fig. 4c,d). Loss of IL6 was likewise associated with a
clear reduction in pulmonary metastasis burden and increased survival
beneﬁt for mice challenged with orthotopic 4T1 tumors, a beneﬁt that
was lost with the concomitant loss of IFNγ (Fig. 4e,f). The corresponding
similarity of the effects of IL6 loss and IDO1 loss on neovascularization
and metastasis susceptibility is consistent with IL6 acting as an impor-
tant downstream mediator of IDO's effects on these processes.
4. Discussion
This report establishes a clear biological role for IDO1 in supporting
pathologic neovascularization and provides evidentiary support for
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the hypothesis that IDO1promotes this outcome through its integration
at the regulatory interface between two competing inﬂammatory cyto-
kines, IFNγ and IL6. Neovascularization was substantially reduced with
the loss of IDO1, and this effectwas completely reversed by the concom-
itant loss of IFNγ, a primary inducer of IDO1. The loss of IL6, known to
exhibit IDO1 dependent expression, likewise resulted in reduced neo-
vascularization that was also determined to be IFNγ dependent. These
effects were initially delineated in the context of OIR, a well-established
model system for the quantiﬁable assessment of neovascularization. Di-
rect tumor relevance was corroborated in an orthotopic 4T1 pulmonary
metastasismodel inwhich corresponding effects on neovascularization,
metastatic tumor burden, and survival were observed.
Although the tolerogenic properties of IDO1 have been extensively
explored, the possibility that IDO1might also impact neovascularization
has not, to this point, been generally recognized nor clearly established
as biologically relevant.While two previous reports did note evidence of
increased vascular density in human xenograft tumors engineered to
overexpress exogenous IDO1 (Nonaka et al., 2011, Li et al., 2006) and
we observed that normal pulmonary vascularization was unexpectedly
diminished in Ido1 nullizygous mice (Smith et al., 2012), the current
study demonstrates, in different disease settings, the importance of
endogenous IDO1 for supporting neovascularization, presents a clear
correlation between IDO1-dependent neovascularization and the
outgrowthof lungmetastases, and providesmechanistic evidence to ex-
plain the basis for this effect by linking IDO1 to regulatory interactions
with the inﬂammatory cytokines IFNγ and IL6.
While further details of IDO1's involvement in neovascularization
remain speculative, the established literature on the cellular andmolec-
ular basis of IDO1's role in immune tolerance will almost certainly in-
form further investigation into the underlying basis for IDO1's role in
supporting neovascularization. In addition to being expressed in im-
mune cells, such as dendritic cells and macrophages, IDO1 expression
in endothelial cells has also been identiﬁed (Blaschitz et al., 2011), and
it will be important to selectively delineate where the expression of
IDO1 is most relevant to its role in neovascularization. Biochemically,
by catabolizing tryptophan, IDO1 can signal through two distinct meta-
bolic pathways, one responding to downstream tryptophan catabolites
and the other to the depletion of tryptophan itself. Both mechanisms
have been linked to the positive regulation of IL6 (DiNatale et al.,
2010, Liu et al., 2014) via kynurenine signaling through AHR (aryl hy-
drocarbon receptor) or amino acid depletion signaling through GCN2
(general nonderepressible 2), but direct relevance to IDO1's role in neo-
vascularization remains to be determined. It is also interesting to spec-
ulate on the biological ramiﬁcations of these new ﬁndings. In the
context of pregnancy where conceptual insight into IDO1's physiologi-
cal relevance was ﬁrst established (Munn et al., 1998), the endometrial
Fig. 2. IDO1 inhibitor treatment negatively affects neovascularization. (a) Representative images of B4-Alexa488-isolectin staining of blood vessels in retinal ﬂatmounts at P17 fromWT
neonates exposed to hyperoxia from P7-P12 to induce OIR and then dosed p.o. with vehicle or 50 mg/kg epacadostat, b.i.d., from P12-P17. (b) Quantitative assessment at P17 of
neovascular area over total retinal area for WT OIR cohorts administered either vehicle or epacadostat together with a third positive control cohort dosed i.p. with 50 mg/kg ethyl
pyruvate b.i.d. (N ≥ 8 eyes). Graphed as means ± SEM with signiﬁcance determined by one-way ANOVA with Dunnett's multiple comparison test. (c) Representative images of
immunoﬂuorescent staining of blood vessels with anti-Cav1 (red) and of nuclei with DAPI (blue) within metastatic regions of lung specimens prepared fromWT mice dosed p.o. with
vehicle or 50 mg/kg epacadostat, b.i.d., over 3 days beginning 3.5 weeks after orthotopic 4T1 mammary tumor cell engraftment. (d) Quantitative assessment of neovascular density
marked by anti-Cav1 positive staining within lung metastases of WT mice administered either vehicle or epacadostat over 3 days together with a third positive control cohort that
received a single i.p. injection of 50 mg/kg cyclophosphamide at 3.5 weeks after orthotopic 4T1 mammary tumor cell engraftment for evaluation 3 days later (N ≥ 3 mice). Graphed as
means ± SEM with signiﬁcance determined by one-way ANOVA with Dunnett's multiple comparison test.
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inﬂammation that develops in response to blastocyst implantation pro-
motes blood vessel formation as well as immune tolerance, both of
which are important for sustaining placentation (Holtan and Creedon,
2011) and both of which, with these new ﬁndings, are now linked to
the involvement of IDO1. Thus, the integrative role proposed for IDO1
in establishing a chronic inﬂammatory environment uniquely suited to
sustain a developing fetus during pregnancy appears, in a different con-
text, to play a pathogenic role in sustaining the development of tumors.
In addition to establishing IDO1's role in supporting neovasculariza-
tion, we have also demonstrated that the use of a pharmacologic inhib-
itor has the potential to be an effective intervention strategy against
neovascularization. In the OIR model, administration of epacodostat
(INCB024360), a speciﬁc, small molecule inhibitor of IDO1 (Liu et al.,
2010), resulted in signiﬁcantly reduced neovascularization relative to
vehicle alone. Likewise, in the 4T1 metastasis model, administration of
epacadostat to mice harboring established, vascularized metastases re-
sulted in a reduced level of neovascularization in response to treatment.
Thus, rather than simply reiterating IDO1's role in supporting
neovascular development, this result indicates that treatment with an
IDO1 inhibitor has the potential to effectively degrade established
neovascular networks. Positive controls for these experiments were se-
lected based on reported anti-neovascular activity in the respective
models, however, possible connections to the IDO1-based mechanism
of action are intriguing. In the OIR model, the anti-neovascular effect
of ethyl pyruvate was proposed to occur through suppression of
HMGB1 (high-mobility group box-1) expression (Lee et al., 2013), how-
ever, the demonstration that ethyl pyruvate is an effective in vivo inhib-
itor of IDO1 expression (Muller et al., 2010), suggests that IDO1 may
Fig. 3. IFNγ is required for the impairedneovascularization andpulmonarymetastasis development that result from IDO1 loss. (a) Representative images of B4-Alexa488-isolectin staining
of blood vessels in retinal ﬂatmounts at P17 from Ifng−/− and Ifng−/− Ido1−/− neonates exposed to hyperoxia from P7-P12 to induce OIR. (b) Quantitative assessment of neovascular area
over total retinal area at P17 for WT, Ido1−/−, Ifng−/− and Ifng−/− Ido1−/− OIR cohorts (N ≥ 14 eyes). Graphed as means ± SEM with signiﬁcance determined by one-way ANOVA with
Tukey'smultiple comparison test. (c) Representative images of immunoﬂuorescent staining of blood vessels with anti-Cav1 (red) and of nuclei with DAPI (blue)withinmetastatic regions
of lung specimens prepared from Ido1−/− and Ifng−/− Ido1−/−mice following orthotopic 4T1 mammary tumor cell engraftment. (d) Quantitative assessment of neovascular density
marked by anti-Cav1 positive staining within lung metastases of WT, Ido1−/−, Ifng−/− and Ifng−/− Ido1−/− mice following orthotopic 4T1 mammary tumor cell engraftment (N ≥ 3
mice). Graphed as means ± SEM with signiﬁcance determined by one-way ANOVA with Tukey's multiple comparison test. (e) Staining of lungs with India ink to visualize the
metastatic burden in Ido1−/− and Ifng−/− Ido1−/− mice at 5 weeks following orthotopic 4T1 mammary tumor cell engraftment. (f) Kaplan-Meier survival curves for cohorts of WT,
Ido1−/−, Ifng−/− and Ifng−/− Ido1−/−mice following orthotopic engraftment of 1 × 104 4T1 cells (N ≥ 17 mice) with signiﬁcance assessed by 2-group log-rank test.
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instead be the relevant target. In established tumor models, the anti-
neovascular effect of cyclophosphamide was shown to be IFNγ-
dependent (Ibe et al., 2001), which, if not directly linked, also suggests
a mechanistic convergence with IDO1.
IDO1 small molecule inhibitors are currently being evaluated in clin-
ical trials for a variety of cancers based on the supposition that they will
help to enable an effective immune response directed against the
tumor. This study indicates, however, that a more complex conceptual-
ization of how the tumor is affectedmay be required to fully understand
any beneﬁcial responses to IDO1 inhibitor treatment. The clear inter-
connection established between the effects of IDO1, IFNγ and IL6 loss
on neovascularization and metastasis survival is consistent with other
indications of the importance of the anti-neovascular effect that IFNγ
exerts against tumors (Qin and Blankenstein, 2000, Qin et al., 2003),
and suggests that the impact on the tumor vasculature should addition-
ally be considered when assessing clinical results obtained with IDO1
inhibitors, particularly in the context of pulmonary metastases. Even
with the data currently at hand, the concept of an IDO1 inhibitor-elicit-
ed, anti-neovascular effect may have explanative value. An emergent
concept in the ﬁeld of angiogenesis is that normalizing pathologic
tumor vasculature will enhance the efﬁcacy of chemo- and radiother-
apies, providing another possible explanation, in addition to enhanced
anti-tumor immunity, for the synergistic responses obtained with com-
binations of IDO1 inhibitors and chemotherapeutic agents in different
mouse tumormodels (Hou et al., 2007,Muller et al., 2005). Additionally,
it was noted in a clinical study that the IDO1 pathway inhibitor,
indoximod, appeared to sensitize tumors to salvage chemotherapy
(Soliman et al., 2013) which would likewise be consistent with the
Fig. 4. IL6 loss results in IFNγ-dependent impairment of neovascularization and pulmonarymetastasis development. (a) Representative images of B4-Alexa488-isolectin staining of blood
vessels in retinal ﬂatmounts at P17 from Ifng−/− and Ifng−/− Il6−/− neonates exposed to hyperoxia from P7-P12 to induce OIR. (b) Quantitative assessment of neovascular area over total
retinal area at P17 forWT, Il6−/−, Ifng−/− and Ifng−/− Il6−/−OIR cohorts (N ≥ 15 eyes). Graphed asmeans± SEMwith signiﬁcance determined by one-way ANOVAwith Tukey'smultiple
comparison test. (c) Representative images of immunoﬂuorescent staining of blood vessels with anti-Cav1 (red) and of nuclei with DAPI (blue) within metastatic regions of lung
specimens prepared fromWT, Il6−/−, Ifng−/− and Ifng−/− Il6−/−mice following orthotopic 4T1 mammary tumor cell engraftment. (d) Quantitative assessment of neovascular density
marked by anti-Cav1 positive staining within lung metastases of WT, Il6−/−, Ifng−/− and Ifng−/− Il6−/−mice following orthotopic 4T1 mammary tumor cell engraftment (N ≥ 3 mice).
Graphed as means ± SEM with signiﬁcance determined by one-way ANOVA with Tukey's multiple comparison test. (e) Staining of lungs with India ink to visualize the metastatic
burden in Il6−/− and Ifng−/− Il6−/− mice at 5 weeks following orthotopic 4T1 mammary tumor cell engraftment. (f) Kaplan-Meier survival curves for cohorts of WT, Il6−/−, Ifng−/−
and Ifng−/− Il6−/−mice following orthotopic engraftment of 1 × 104 4T1 cells (N ≥ 9 mice) with signiﬁcance assessed by 2-group log-rank test.
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possibility of vascular normalization improving chemotherapy re-
sponses. Alternatively, IDO1 inhibition may enhance the IFNγ-depen-
dent, anti-angiogenic effect elicited by certain chemotherapeutic drugs
such as cyclophosphamide, which has been reported to produce im-
mune-dependent rejection of large, vascularized tumors mediated by
the destruction of tumor blood vessels in a manner that requires IFNγ
receptor expression on normal host cells (Ibe et al., 2001). By eliminat-
ing the negative feedback constraint imposed by IDO1 on the anti-an-
giogenic effect of IFNγ, IDO1 inhibitors may be able to enhance this
aspect of the therapeutic response to cyclophosphamide and perhaps
other chemotherapeutic drugs that have also been identiﬁed as having
anti-angiogenic activity, such as taxanes (Bocci et al., 2002).
Beyond cancer treatment, the results of this study suggest potential
utility for IDO1 inhibitors in treating the pathologic neovascularization
associated with retinopathies. Retinopathy of prematurity is the most
obvious indication in which to evaluate the potential beneﬁt of IDO1 in-
hibition given that this is the disease that the OIR protocol most closely
models. Additionally, however, a number of other retinopathies might
also beneﬁt from IDO1 inhibitor treatment as indicated by the effective-
ness of the anti-VEGF-A antibody Fab, ranibizumab, for treating diseases
such aswetmacular degeneration and diabetic retinopathy (Triantafylla
et al., 2014). Despite the effectiveness of anti-VEGF-A antibody therapy
for treating various ocular diseases, there are also notable drawbacks
to its use. One signiﬁcant downside of blocking VEGF-A is the collateral
interference with normal angiogenesis that occurs in conjunction with
the beneﬁcial reduction in neovascularization. Evidence from the OIR
model suggests that, while targeting IDO1 is comparably effective to
targeting VEGF-A in interferingwith neovascularization, IDO1 inhibition
does not appear to interferewith normal angiogenesis based on the lack
of effect of IDO1 loss on the development of retinal vasculature in
normoxic mice as well as the degree of recovery that occurs in the avas-
cular region of Ido1−/−mice in the context of OIR. Additionally, itmay be
possible to develop a therapeutic formulation of a small molecule IDO1
inhibitor that does not involve direct injection into the eye as is required
with antibody-based therapy. Clearly, the recognition that IDO1 plays a
key role in supporting inﬂammatory neovascularization opens up
compelling avenues of basic biological investigation and potential
therapeutic intervention centered around this key nodal regulator of
the inﬂammatory environment.
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